High Risk

27 registered clinical trials studyying High Risk — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Venetoclax Combined With Azacitidine for Consolidation Therapy in AML NCT07425782	The First Affiliated Hospital of Soochow University	Phase 2
Not Yet Recruiting	Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas NCT07129499	Jiangsu Famous Medical Technology Co., Ltd.	N/A
Completed	Guardians Receiving Information Through Navigators NCT07147244	KDH Research & Communication	N/A
Recruiting	Remote Cardiotocography Telemonitoring Within High-risk Pregnancy Care NCT07124325	Birmingham Women's NHS Foundation Trust	N/A
Completed	Monitoring and Outreach for Maternal Safety Postpartum NCT06899737	KDH Research & Communication	N/A
Recruiting	Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevo NCT06624696	Sun Yat-sen University	Phase 4
Recruiting	A Cohort Study of Disease Prediction Model for High-risk Population With Bipolar Disorder NCT07031661	Shanghai Mental Health Center	—
Recruiting	Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection NCT06409702	The First Affiliated Hospital of Soochow University	Phase 4
Recruiting	Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk NCT05877573	Nanfang Hospital, Southern Medical University	N/A
Not Yet Recruiting	Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study) NCT05778097	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 2
Completed	General Decolonization With Octenisan® Set Before Elective Orthopedic Surgery NCT05647252	Balgrist University Hospital	Phase 3
Unknown	Designing a Personalized Diet to Reduce the Risk of Crohn's Disease Onset NCT05566587	Mount Sinai Hospital, Canada	N/A
Unknown	A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer NCT05430737	West China Hospital	N/A
Unknown	Tauropace to Prevent Cardiac Implantable Device Infections in Heart Failure Patients NCT05103267	Federico II University	—
Unknown	Imaging vs. no Testing in Asymptomatic High-risk Diabetic Patients NCT04388280	Clinical Centre of Serbia	N/A
Unknown	Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which NCT04730232	Tianjin Medical University Second Hospital	Phase 2
Completed	68 Ga-PSMA for High Risk Prostate Cancer NCT04614363	The Methodist Hospital Research Institute	Phase 1 / Phase 2
Unknown	VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma NCT03641456	Sun Yat-sen University	Phase 2
Completed	Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman NCT04548102	Cairo University	N/A
Active Not Recruiting	Integrative Sequencing In Germline and Hereditary Tumours NCT03857594	University Health Network, Toronto	—
Completed	Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma NCT02650648	Memorial Sloan Kettering Cancer Center	Phase 1
Recruiting	Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy NCT07074951	St. Petersburg State Pavlov Medical University	N/A
Terminated	Enhancing Father's Ability to Support Their Preschool Child NCT01395238	Queens College, The City University of New York	N/A
Completed	Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" NCT01030861	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Unknown	A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients NCT01788137	Sun Yat-sen University	Phase 3
Completed	Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission NCT04298619	Federico II University	—
Completed	Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential NCT00590785	National Cancer Institute (NCI)	Phase 3